The Children's Heart Foundation celebrates 25 years of funding the most promising CHD research! Tweet this "If it were not for our fabulous volunteers and donors, CHF would not exist, period!" says Betsy Peterson, the organization's founder. "I'm so grateful to each and every one of you who has ensured that much needed research for congenital heart defects gets funded." The 25th Anniversary campaign will showcase the role research has played, highlighting breakthrough science and the researchers who led it. There will be opportunities to pay tribute to heart warriors and angels, as well as ways to become a community champion or partner. As much as there is to celebrate, the CHF says that this 25th Anniversary is also a call to action. Each year, research goes unfunded due to the disproportionate lack of funding CHD receives given its prevalence. "Now as we look forward to the next 25 years, our volunteers and donors will play an even bigger role in helping The Children's Heart Foundation meet the demand for funding future CHD research," Peterson stated.CEO Gail Roddie-Hamlin stated, "Our current efforts have been great, but we cannot be satisfied. We must meet the challenges of the next 25 years through continued fundraising, advocacy, and community expansion to fund the best science and research endeavors for all those affected by CHD."Founder Betsy Peterson summed up the organization's goals by stating, "As the mother of a child born with complex congenital heart defects, I know that if it had not been for research, our son Sam would not have lived more than a day. If you think about it, we all stand on the shoulders of those that have gone on before us."Visit The Children's Heart Foundation's website to learn more about the organization's mission at www.childrensheartfoundation.org.SOURCE The Children's Heart Foundation Related Links http://www.childrensheartfoundation.org

EDMONTON, AB, May 6, 2021 /PRNewswire/ - Medo, an artificial intelligence technology start-up company headquartered in Singapore and Canada, is pleased to announce that it has received 510(k) clearance from the U.S. Food and Drug Administration for the world's first tool using Artificial Intelligence to drastically simplify the Thyroid ultrasound scanning workflow. The company previously announced the release of an AI assistant for helping diagnose hip dysplasia and is now expanding their technology into other use cases. Over 1.5 million thyroid ultrasound exams are done each year in the USA alone. This high volume is due to the fact that lumps, or "nodules" on the thyroid gland are common and although usually benign, can be cancerous. Each ultrasound exam is non-invasive and safe, but incredibly time consuming and potentially error-prone, involving a tedious review of hundreds of images to locate and measure thyroid nodules individually. This process becomes even more difficult and subjective when the gland has multiple nodules. Using artificial intelligence, Medo has revolutionized the process of performing thyroid studies and turned it into a seamless, fast, and objective workflow. With Medo-Thyroid, the user simply obtains quick video 'sweeps' of each side of the thyroid gland. Medo-Thyroid then seamlessly uses AI to automatically review this data  and a) select the optimal images for analysis, b) calculate standard lobe and isthmus measurements, and c) assist to locate, measure and characterize any nodules present using the well-known TI-RADS system. With this information and a single click, Medo-Thyroid creates an individualized interactive report. Dr. Jacob Jaremko, a radiologist and co-founder of Medo, explains that "Medo-Thyroid makes thyroid ultrasound a less frustrating test, by presenting thyroid measurements and nodule characteristics in a convenient format. It's especially helpful to radiologists when following up multiple nodules." Medo-Thyroid contains several key technological breakthroughs, including a cross-referencing ability previously only possible on multi-plane CT and MRI. This feature is designed to assist the user with viewing individual nodules across all planes of interest such as transverse and sagittal. Dr. Dornoosh Zonoobi, co-founder and CEO of Medo, notes that: "With this product, Medo provides both clinical and financial value to the stakeholders. We are particularly pleased with the feedback we have received from many of the independent clinicians who have used our product  stating that this will greatly benefit them in their everyday workflow." About MEDO.ai MEDO is an artificial intelligence technology start-up company dual headquartered in Edmonton, Canada and Singapore. MEDO builds cutting edge artificial intelligence that pairs with ultrasound devices to facilitate novice users' ability to detect common and critical conditions, even in remote and rural areas. MEDO believes that such technology will transform ultrasound for the 21st century. For more information, visit https://medo.ai/. SOURCE Medo Related Links www.medo.ai